Share this Page:
The National Institute for Health and Care Excellence (NICE) published final guidance recommending use of nivolumab (Opdivo) as a treatment option for people with previously treated advanced renal cell carcinoma (RCC).
Clinical trials have shown that patients treated with nivolumab after their previous therapy was no longer effective lived for an average of 5.4 months longer than those who received standard targeted therapy (everolimus; 25 months versus 19.6 months, respectively). Nivolumab also provided an improved quality of life as patients experienced fewer serious treatment-related side effects.
The final guidance can be found on the NICE website here, along with information for the public.